The corona pandemic and multiple sclerosis : vaccinations and their implications for patients-Part 2: vaccine technologies
© 2021. The Author(s)..
Along with the challenges posed by the globally circulating COVID-19 pandemic, there have been some epochal advances in the field of vaccine technologies. In addition to the traditionally used dead, live and protein-based vaccines, vector-based and gene-based vaccines gained enormous attention in the course of this health crisis. The aim of this article is to provide an overview of multiple sclerosis (MS) and vaccination, recent advances in the SARS-CoV‑2 vaccine landscape as well as a detailed discussion of the various vaccine technologies. Finally, clear recommendations in the context of disease-modifying treatment and vaccination in MS are highlighted.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:92 |
|---|---|
| Enthalten in: |
Der Nervenarzt - 92(2021), 12 vom: 15. Dez., Seite 1283-1292 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
Die Corona-Pandemie und Multiple Sklerose: Impfungen und deren Implikationen für Patienten – Teil 2: Impfstofftechnologien |
|---|
| Beteiligte Personen: |
Monschein, Tobias [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 08.12.2021 Date Revised 12.08.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00115-021-01154-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327784180 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327784180 | ||
| 003 | DE-627 | ||
| 005 | 20231225201542.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1007/s00115-021-01154-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1092.xml |
| 035 | |a (DE-627)NLM327784180 | ||
| 035 | |a (NLM)34232358 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Monschein, Tobias |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The corona pandemic and multiple sclerosis |b vaccinations and their implications for patients-Part 2: vaccine technologies |
| 246 | 3 | 3 | |a Die Corona-Pandemie und Multiple Sklerose: Impfungen und deren Implikationen für Patienten – Teil 2: Impfstofftechnologien |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.12.2021 | ||
| 500 | |a Date Revised 12.08.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s). | ||
| 520 | |a Along with the challenges posed by the globally circulating COVID-19 pandemic, there have been some epochal advances in the field of vaccine technologies. In addition to the traditionally used dead, live and protein-based vaccines, vector-based and gene-based vaccines gained enormous attention in the course of this health crisis. The aim of this article is to provide an overview of multiple sclerosis (MS) and vaccination, recent advances in the SARS-CoV‑2 vaccine landscape as well as a detailed discussion of the various vaccine technologies. Finally, clear recommendations in the context of disease-modifying treatment and vaccination in MS are highlighted | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Gene-based | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Vaccine technologies | |
| 650 | 4 | |a Vector | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 700 | 1 | |a Zrzavy, Tobias |e verfasserin |4 aut | |
| 700 | 1 | |a Löbermann, Micha |e verfasserin |4 aut | |
| 700 | 1 | |a Winkelmann, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Berger, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Rommer, Paulus |e verfasserin |4 aut | |
| 700 | 1 | |a Hartung, Hans-Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Zettl, Uwe K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Der Nervenarzt |d 1947 |g 92(2021), 12 vom: 15. Dez., Seite 1283-1292 |w (DE-627)NLM000034320 |x 1433-0407 |7 nnns |
| 773 | 1 | 8 | |g volume:92 |g year:2021 |g number:12 |g day:15 |g month:12 |g pages:1283-1292 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00115-021-01154-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 92 |j 2021 |e 12 |b 15 |c 12 |h 1283-1292 | ||